Bad news for Novo Nordisk (NVO-17.09%) Friday was good news for Eli Lilly (LLY 4.98%) and Viking Therapeutics (VKTX 6.01%), ...

Shares in Novo Nordisk plunged 20% on Friday.

Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently ...

Pedersen and Mariam Sunny LONDON/COPENHAGEN (Reuters) -Novo Nordisk shareholders were seeking on Friday to find out why such ...

Illustration: Elizabeth Smelov Novo Nordisk shares dived Friday after an experimental anti-obesity treatment missed ...

Novo Nordisk stock fell sharply early Friday after the pharmaceutical giant, known for its blockbuster drugs Ozempic and ...

Investors and analysts had eagerly awaited this data as a test of Novo’s case that it has a strong pipeline of drugs to ...

An experimental Novo Nordisk anti-obesity treatment helped patients lose less than a quarter of their bodyweight in a new ...

Las acciones de la farmaceútuca danesa Novo Nordisk A/S registraron la mayor caída de su historia tras informar resultados ...

The Ozempic maker's stock tanked after its highly anticipated CagriSema drug trial showed an average of 22.7% weight loss, ...

Novo Nordisk ( NVO) reported its newest GLP-1 product, CagriSema, provides an average of 22.7% weight loss, but that wasn't ...

Novo Nordisk's CargiSema Phase III trial showed significant weight loss but failed reach ambitious targets set by management.